Revelation Biosciences is developing its proprietary Gemini platform targeting inflammation in acute and chronic kidney diseases, conditions with no approved targeted therapies. Despite promising early clinical and preclinical data, the company remains in a net loss position with no revenue, facing operating and regulatory challenges including FDA staffing cuts and single-source supply risks. Capital preservation efforts feature multiple reverse stock splits against a backdrop of persistent cash burn, as the company prepares for pivotal Phase 2/3 trials and toxicology studies. Near-term catalysts hinge on clinical milestone deliveries amid significant operational risks.